Peritoneal neoplasm is a rare but serious cancer affecting the delicate tissue lining the abdominal cavity. Understanding treatment pathways—from established medical approaches to innovative therapies being tested—can help patients and families navigate this complex diagnosis with greater confidence.

Understanding Treatment Goals and Pathways

When someone receives a diagnosis of peritoneal neoplasm, the main goals of treatment focus on removing or reducing cancerous tissue, managing symptoms, preventing the spread of disease, and improving quality of life. Treatment planning depends heavily on several factors, including whether the cancer started in the peritoneum itself or spread from another organ, the extent of disease throughout the abdominal cavity, and the patient’s overall health and ability to tolerate intensive procedures.^[1]

Medical teams typically include specialists from multiple disciplines—surgical oncologists who perform complex abdominal operations, medical oncologists who manage chemotherapy and targeted drugs, and radiation oncologists when radiation therapy might help. This team approach ensures that each patient receives personalized care tailored to their specific situation.^[2]

Treatment options fall into two broad categories: standard therapies that medical societies and guidelines already recommend, and experimental approaches being studied in clinical trials—research studies that test new treatments before they become widely available. Because peritoneal neoplasm often presents at advanced stages when symptoms finally appear, treatment strategies frequently combine multiple approaches to achieve the best possible outcomes.^[3]

Standard Treatment Approaches

Cytoreductive Surgery

Cytoreductive surgery, also called debulking surgery, represents the cornerstone of peritoneal cancer treatment. During this extensive operation, surgeons work methodically to remove all visible cancerous tissue from the peritoneum and affected organs. The procedure can take six to nine hours, as surgeons must carefully inspect the entire abdominal cavity, removing tumor deposits from multiple locations.^[10]

The decision to proceed with cytoreductive surgery depends on whether surgeons believe they can remove most or all visible disease. Not every patient qualifies for this approach—if cancer has spread too extensively or involved critical blood vessels and organs beyond safe removal, surgery may not be advisable. Doctors often use imaging scans and sometimes exploratory laparoscopy to assess whether surgery will help before committing to the full procedure.^[9]

Recovery from cytoreductive surgery typically requires a hospital stay of seven to fourteen days. The body needs time to heal from such major abdominal surgery, and patients often need support managing pain, nutrition, and gradually returning to normal activities. While the surgery itself carries risks—including infection, bleeding, and complications related to removing portions of affected organs—it offers the possibility of extending survival when combined with additional treatments.^[10]

HIPEC: Heated Intraperitoneal Chemotherapy

Immediately following cytoreductive surgery, many patients receive a specialized treatment called hyperthermic intraperitoneal chemotherapy, or HIPEC. This innovative approach delivers heated chemotherapy solution directly into the abdominal cavity during the same operation. The solution, warmed to approximately 107 degrees Fahrenheit, bathes the entire peritoneal surface for about ninety minutes while being gently circulated.^[10]

Heating the chemotherapy serves important purposes. The elevated temperature helps cancer-fighting drugs penetrate deeper into tissue, potentially reaching microscopic cancer cells that remain after visible tumors are removed. Heat itself also damages cancer cells, making them more vulnerable to the chemotherapy drugs. Because the medication stays confined to the abdominal cavity rather than circulating through the bloodstream, doctors can use higher concentrations while causing fewer side effects throughout the rest of the body.^[13]

The chemotherapy agents most commonly used in HIPEC include cisplatin, mitomycin, and doxorubicin. Each works by interfering with cancer cells’ ability to grow and divide. The specific drug chosen depends on the type of primary cancer that led to peritoneal disease. HIPEC has shown promising results in helping people live longer and preventing cancer from returning in the peritoneum.^[13]

Systemic Chemotherapy

Many patients receive standard chemotherapy that travels throughout the bloodstream, either before surgery to shrink tumors, after surgery to eliminate remaining cancer cells, or when surgery isn’t possible. For peritoneal neoplasm, the first-line chemotherapy typically combines a platinum agent (such as cisplatin or carboplatin) with a taxane (such as paclitaxel).^[13]

Platinum drugs work by damaging the DNA inside cancer cells, preventing them from dividing and eventually causing cell death. Taxanes interfere with the cell structures that allow cancer cells to divide. Using these medications together attacks cancer through different mechanisms, making the treatment more effective than either drug alone. The duration of chemotherapy varies—some patients receive several cycles over months, while others may continue treatment longer depending on how well the cancer responds.^[13]

Chemotherapy inevitably causes side effects because it affects rapidly dividing cells throughout the body, not just cancer cells. Common problems include fatigue, nausea, hair loss, increased infection risk due to lowered blood cell counts, and numbness or tingling in hands and feet called peripheral neuropathy. Medical teams work closely with patients to manage these effects through medications, dose adjustments, and supportive care. Most side effects gradually improve after treatment ends.^[1]

Targeted Therapy

Targeted therapy represents a more precise approach than traditional chemotherapy. These medications attack specific abnormalities in cancer cells or target particular molecules that help tumors grow and spread. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies home in on characteristics unique to cancer cells, potentially causing fewer side effects.^[1]

For patients with peritoneal cancer, especially when connected to ovarian cancer, targeted drugs may include VEGF inhibitors, which block signals that tumors use to grow new blood vessels. Without adequate blood supply, tumors struggle to grow and spread. Another important category involves medications for patients with specific genetic mutations. For example, women with BRCA1 or BRCA2 gene mutations who develop peritoneal cancer may benefit from drugs called PARP inhibitors, such as olaparib, which exploit cancer cells’ DNA repair weaknesses.^[13]

Before prescribing targeted therapy, doctors test cancer cells to identify whether specific targets exist. Not every patient’s cancer will have the particular characteristics that a targeted drug attacks, so these tests help ensure the right treatment reaches the right patient. This personalized approach increasingly guides cancer treatment decisions.^[1]

Radiation Therapy

While less commonly used for peritoneal neoplasm than for other cancers, radiation therapy sometimes helps in specific situations. This treatment uses high-energy beams to damage cancer cells’ DNA, preventing them from growing and dividing. Radiation might be recommended for patients with advanced disease in particular locations, when cancer returns after initial treatment, or to relieve symptoms such as pain from tumor pressure on organs.^[1]

Radiation treatment typically involves multiple sessions over several weeks, with each session lasting only minutes. The actual treatment is painless, though side effects can develop as radiation affects both cancer and nearby healthy tissue. Common problems include fatigue, skin irritation in the treatment area, and digestive upset if abdominal organs receive radiation. Most side effects gradually resolve after treatment concludes.^[10]

Treatment in Clinical Trials

Understanding Clinical Trial Phases

Clinical trials test new treatments through carefully designed research studies before those treatments become standard care. These studies progress through distinct phases, each answering different questions. Phase I trials focus primarily on safety—researchers determine appropriate doses and watch for side effects in small groups of patients. Phase II trials expand to larger groups to assess whether the treatment shows signs of working against cancer. Phase III trials compare the new treatment directly against current standard therapy in large patient populations to determine if it offers meaningful advantages.^[2]

Participating in clinical trials gives patients access to cutting-edge treatments years before they become widely available. While trials involve uncertainty—researchers don’t yet know definitively how well experimental treatments work—they’re carefully monitored for safety and often represent the best hope for people whose cancer hasn’t responded adequately to standard approaches.^[2]

Immunotherapy Approaches

Immunotherapy harnesses the body’s own immune system to fight cancer. Unlike chemotherapy that directly attacks cancer cells, immunotherapy trains immune cells to recognize and destroy tumors. Several immunotherapy approaches are being tested for peritoneal neoplasm in clinical trials.^[13]

Immune checkpoint inhibitors represent one promising category. Cancer cells often exploit molecular “brakes” that normally prevent the immune system from attacking the body’s own tissues. Checkpoint inhibitors release these brakes, allowing immune cells to mount stronger attacks against tumors. Pembrolizumab, which blocks a checkpoint molecule called PD-1, received FDA accelerated approval for certain solid tumors, including some cases of mesothelioma affecting the peritoneum. This drug is being studied in patients whose tumors show specific characteristics and haven’t responded to standard treatments.^[13]

Researchers are also exploring combinations of checkpoint inhibitors with chemotherapy or other immunotherapy drugs. The theory behind combination approaches suggests that different treatments might work together synergistically—chemotherapy can damage tumors in ways that make them more visible to the immune system, while immunotherapy provides the immune reinforcements to attack effectively. Early results from some trials show promise, though more research continues.^[13]

During HIPEC procedures, some clinical trials are testing the addition of immunotherapeutic agents such as interleukins and interferons to the heated chemotherapy solution. These immune-stimulating proteins might enhance the treatment’s effectiveness by mobilizing local immune responses within the abdominal cavity while the heated chemotherapy attacks cancer cells directly.^[13]

Novel Molecular Targets

Scientists continuously identify new molecular pathways that cancer cells use to survive and spread. Targeting these pathways with specialized drugs represents an active area of clinical research. For peritoneal mesothelioma, one promising direction involves phosphatidylinositol-3-kinase, or PI3K—a protein that helps regulate cell growth and survival. Preclinical studies suggest that blocking PI3K activity might slow or stop peritoneal mesothelioma growth, leading to clinical trials testing PI3K inhibitors in patients.^[13]

Another research avenue explores drugs that interfere with how cancer cells use nutrients and energy. Cancer cells often reprogram their metabolism to support rapid growth, creating vulnerabilities that targeted drugs might exploit. Trials testing metabolic inhibitors aim to essentially starve tumors of the resources they need while sparing normal cells.^[13]

Advanced Chemotherapy Delivery Methods

Beyond HIPEC, researchers are developing additional ways to deliver chemotherapy more effectively to peritoneal tumors. Early postoperative intraperitoneal chemotherapy, or EPIC, involves delivering chemotherapy directly into the abdomen through catheters over several days following cytoreductive surgery. This approach aims to eliminate microscopic cancer cells that might remain after surgery and HIPEC.^[12]

Some trials examine different drug combinations and temperatures for HIPEC, seeking the optimal balance between cancer-killing effectiveness and tolerability. Others test new chemotherapy agents specifically for intraperitoneal delivery, including drugs that haven’t traditionally been used this way but show promise in laboratory studies.^[12]

Biomarker-Guided Treatment Selection

Clinical trials increasingly incorporate sophisticated testing of patients’ tumors to identify genetic mutations, protein expressions, and other characteristics that might predict treatment response. This approach, sometimes called precision oncology, matches patients to treatments most likely to help their specific cancer.^[1]

For example, trials might test whether patients whose tumors show high levels of certain immune markers respond better to immunotherapy, or whether particular genetic mutations make cancers more vulnerable to specific targeted drugs. Blood tests looking for circulating tumor DNA—small fragments of cancer DNA floating in the bloodstream—are being studied as tools to monitor treatment effectiveness and detect cancer recurrence earlier than traditional imaging.^[9]

Trial Locations and Access

Clinical trials for peritoneal neoplasm take place at specialized cancer centers worldwide, particularly those with expertise in complex peritoneal surface malignancies and HIPEC procedures. Major academic medical centers in the United States, Europe, and other developed regions commonly offer trials. Patients can search clinical trial databases to find studies accepting participants, though discussion with oncologists familiar with the patient’s specific situation remains essential for identifying appropriate options.^[2]

Eligibility criteria vary by study but typically consider factors such as the type and stage of peritoneal cancer, previous treatments received, extent of disease spread, overall physical condition, and presence of specific genetic or molecular characteristics in the tumor. Some trials specifically seek patients whose disease hasn’t responded to standard treatments, while others test new approaches as first-line therapy. Trial participation usually requires regular visits to the study site for treatments and monitoring, which can pose logistical challenges for patients living far from participating centers.^[13]

Most Common Treatment Methods

• Cytoreductive Surgery with HIPEC
  • Extensive surgery to remove all visible tumor tissue from the peritoneum and affected organs, taking six to nine hours
  • Immediately followed by heated chemotherapy solution circulated through the abdomen for ninety minutes
  • Chemotherapy agents commonly include cisplatin, mitomycin, or doxorubicin heated to approximately 107 degrees Fahrenheit
  • Requires seven to fourteen day hospital stay for recovery
  • Best outcomes at specialized high-volume centers with experienced surgical teams
• Systemic Chemotherapy
  • First-line regimens typically combine platinum agents (cisplatin or carboplatin) with taxanes (paclitaxel)
  • Can be given before surgery to shrink tumors, after surgery to eliminate remaining cells, or for palliative care
  • Multiple cycles administered over several months depending on treatment response
  • Common side effects include fatigue, nausea, hair loss, lowered blood counts, and peripheral neuropathy
• Targeted Therapy
  • VEGF inhibitors block blood vessel growth needed for tumor expansion
  • PARP inhibitors like olaparib for patients with BRCA1 or BRCA2 mutations
  • Requires tumor testing to identify specific molecular targets before treatment selection
  • Generally causes fewer side effects than traditional chemotherapy
• Immunotherapy
  • Checkpoint inhibitors such as pembrolizumab that release immune system brakes against cancer
  • Interleukins and interferons being tested in combination with HIPEC in clinical trials
  • Most research conducted in pleural mesothelioma with limited specific data for peritoneal disease
  • Accelerated FDA approval for pembrolizumab in certain unresectable solid tumors
• Radiation Therapy
  • High-energy beams used in specific situations for advanced or recurrent disease
  • May help relieve symptoms such as pain from tumor pressure
  • Typically involves multiple sessions over several weeks
  • Side effects include fatigue, skin irritation, and digestive upset